ACTRN12614000962639已完成2 期
An open-label, phase 2, single centre, randomised, crossover pharmacokinetic study assessing two application areas of 0.5ml (5mg) testosterone 1% cream, ANDROFEME(Registered trademark) in healthy postmenopausal women
awley Pharmaceuticals0 个研究点目标入组 20 人开始时间: 2014年9月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 45 Years 至 65 Years（—）
- 性别
- Female
入选标准
- •Healthy naturally postmenopausal women aged 45-65 years
排除标准
- •Allergy to almonds, major medical conditions or on recent hormonal treatment
研究者
相似试验
已完成
2 期
Bioequivalence study comparing AndroForte 5 (Registered Trademark (R)) and Testogel (R) 1%Testosterone replacement therapyHypogonadismMetabolic and Endocrine - Normal metabolism and endocrine development and functionACTRN12610000834055awley Pharmaceuticals16
进行中（未招募）
不适用
A randomized, open label, single center, phase IIa controlled trial to assess tolerability, safety and effect of treatment with deferasirox plus standard antiviral therapy versus standard antiviral therapy in chronic hepatitis C patients na?ve to treatment with interferon and/or ribavirin - NDChronic hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912EUCTR2009-012344-17-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA
已完成
2 期
Safety and immune response of the malaria vaccine, R21/Matrix-M™, in Thai adultsMalaria vaccine in healthy volunteersISRCTN57717892niversity of Oxford127
进行中（未招募）
1 期
A single center, phase II, open label randomized clinical trial to evaluate the inhibition of ovulation of three prolonged release formulations containing a combination of gestagen and oestrogen versus a conventional flexible regimen contraceptive in 100 healthy women.EUCTR2016-003830-26-DEExeltis France100
进行中（未招募）
1 期
A Phase II, Single Centre, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy InfantsEUCTR2006-003476-35-GBovartis Vaccines and Diagnostics S.r.l216